ALYFTREK's Patent Shield Extended: FDA Calls for Challenges
Published Date: 2/13/2026
Notice
Summary
The FDA has set the official review period for ALYFTREK, a new drug, so its patent holder can apply for extra patent time. This helps the company protect their invention longer, potentially delaying generic competition and affecting drug prices. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they have until April or August 2026 to speak up.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Drug patent review period set
The FDA found that ALYFTREK had a regulatory review period of 5,335 days (5,102 days testing phase and 233 days approval phase). The testing phase began May 15, 2010; the new drug application was submitted May 2, 2024; and FDA approved the application on December 20, 2024. The applicant is seeking 1,826 days of patent term extension, and FDA’s determination establishes the maximum potential length of a patent extension.
Public comment and petition windows
Anyone who thinks the published dates are wrong can submit comments requesting a redetermination by April 14, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by August 12, 2026. Instructions for electronic and written submissions are provided in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-02967, Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to keep collecting important info from the public. If you or your group deal with Medicare or Medicaid, this affects you! You’ve got until March 16, 2026, to share your ideas on how to make this process easier and better, with no new costs announced.
Next: 2026-02969, Notice of Petition for Extension of Waiver of Compliance
The Association of American Railroads (AAR) asked the Federal Railroad Administration (FRA) to extend a break from some air brake maintenance rules for certain electronic brake systems. This means trains using these brakes can wait longer between checkups, thanks to a strong safety record. If you want to share your thoughts, make sure to comment by March 16, 2026!